Related Experiment Video
Updated: Jun 23, 2026

MRI Mapping of Cerebrovascular Reactivity via Gas Inhalation Challenges
Published on: December 17, 2014
Carbon monoxide: vascular therapeutic for the future
1Department of Surgery, University of Pittsburgh, Pittsburgh, PA 15213, USA. tzenge@upmc.edu
Carbon monoxide (CO) is now recognized for therapeutic benefits, including anti-inflammatory and cytoprotective effects. Its potential as a vascular therapeutic, particularly in inhibiting intimal hyperplasia, is a key focus.
Area of Science:
- Biochemistry
- Pharmacology
- Vascular Biology
Background:
- Carbon monoxide (CO) was historically viewed solely as a toxic gas.
- Emerging research highlights CO's therapeutic potential, shifting its scientific perception.
- CO exhibits anti-inflammatory, cytoprotective, and vasoprotective properties.
Purpose of the Study:
- To provide a historical overview of carbon monoxide biology.
- To summarize CO's role in modulating various diseases.
- To explore CO's potential as a vascular therapeutic agent, focusing on intimal hyperplasia.
Main Methods:
- Literature review of carbon monoxide research.
- Analysis of studies on CO's biological functions and disease modulation.
- Focus on CO's effects on vascular health and intimal hyperplasia.
Main Results:
- CO demonstrates significant anti-inflammatory and cytoprotective activities.
- CO possesses vasoprotective properties, notably inhibiting intimal hyperplasia.
- Evidence supports CO's therapeutic utility in various disease contexts.
Conclusions:
- Carbon monoxide has evolved from a toxin to a promising therapeutic agent.
- CO's vasoprotective effects, especially against intimal hyperplasia, warrant further investigation for vascular therapies.
- This review underscores CO's multifaceted biological roles and therapeutic promise.
Related Concept Videos
Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue, improving...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
Carbon Dioxide Transport in the Blood
Forms of CO2 Transport
1. Dissolved in plasma: A small percentage (7-10%) of CO2 is transported and dissolved directly in the plasma.
2. Carbaminohemoglobin: Just over 20% of CO2 is chemically bound to...
Chronic Obstructive Pulmonary Disease-V: Management
Smoking Cessation
Adrenergic Agonists: Therapeutic Uses
Emergency and Intensive Care Unit (ICU) applications: Pressor agents increase blood pressure, heart rate, and contractility in shock and organ failure situations. Dopamine can induce vasodilation and stimulate adrenoceptors. Endogenous catecholamines are effective in treating cardiogenic shock. α2-agonists like clonidine can reverse anesthesia-induced hypertension.
Allergies and anaphylaxis:...
